Windtree Therapeutics, a biotechnology company specializing in oncology and cardiovascular treatments, announced a new $520 million funding package to support a cryptocurrency treasury strategy focused on BNB token acquisition.
According to the company’s press release, $500 million will be assigned to develop an equity line of credit (ELOC) to augment its BNB cryptocurrency purchases. The remaining $20 million will be invested in a stock purchase agreement with Build and Build Corp, a digital and financial solutions company. The firm plans to allocate 99% of the funds to acquire the BNB cryptocurrency. BNB is the native cryptocurrency of the Binance ecosystem.
Jed Lathen, CEO of Windtree, said, “We are excited to incorporate these new facilities to enable our future BNB acquisitions as part of our BNB treasury strategy. Pending stockholder approval, the opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy.”
Windtree’s move represents a strategic shift for the pharmaceutical sector, where companies traditionally have conservative treasury strategies. The move to set up the ELOC and BNB treasury by the biotech company shows its intent to diversify its treasury assets, take advantage of blockchain technology, and integrate it with its financial ecosystem. However, the firm did emphasize that implementation of the ELOC facility requires stockholder approval,
Meanwhile, Windtree has a diverse ongoing pipeline of projects dealing with the creation of medicines for acute diseases. The company’s latest drug, Istaroxime, is in Phase 2b.
Also Read: 21Shares Partners with Societe Generale to Expand Crypto ETPs Access
